Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. The Company’s drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder (AUD). AD04 is used for the treatment of AUD in subjects with certain target genotypes, which were identified using its companion diagnostic genetic test. AD04 is a genetically targeted, serotonin-3 receptor antagonist, a therapeutic agent for the treatment of AUD. The Company’s AD04 also has the potential to treat other addictive disorders such as opioid use disorder, gambling, and obesity. The Company is also developing adenosine analogs for the treatment of pain and other disorders.